eragidomide

Drug Overview

Eragidomide is an innovative medicine being developed to treat aggressive blood cancers. It is considered a Targeted Therapy and a “Smart Drug” because it does not just attack all cells in the body. Instead, it is designed to find and destroy a specific protein that cancer cells need to survive.

Because it helps the body clear out “bad” proteins, it belongs to a modern class of drugs known as CELMoDs (Cereblon E3 Ligase Modulators). This medicine represents a new frontier in how we treat diseases at a molecular level, focusing on the cell’s own cleaning system.

• Generic Name: Eragidomide (also known as CC-90009).
• US Brand Names: None (Currently an Investigational Drug).
• Drug Class: Cereblon E3 Ligase Modulator (CELMoD); Protein Degrader.
• Route of Administration: Intravenous (IV) Infusion.
• FDA Approval Status: Investigational. It is currently being tested in clinical trials and is not yet approved for general use.

What Is It and How Does It Work? (Mechanism of Action)

Eragidomide works by using the cell’s internal “trash disposal” system to kill cancer. Every cell has a system that identifies old or broken proteins and shreds them. Eragidomide “tricks” this system into shredded a protein that the cancer cell needs to stay alive.

Molecular Level Activity

Inside a cancer cell, there is a protein called GSPT1. This protein is vital because it tells the cell how to finish making other proteins. Without GSPT1, the cancer cell cannot function and will eventually die (a process called apoptosis).

Eragidomide acts as a “molecular glue” in the following steps:

1. The Connection: The drug binds to a protein in the cell called Cereblon, which is part of a “cleaning crew” (the E3 ubiquitin ligase complex).
2. The Target: Once eragidomide is attached to Cereblon, it changes the shape of the cleaning crew so it can grab onto the GSPT1 protein.
3. The Tagging: The cleaning crew puts a “trash tag” (called ubiquitin) onto the GSPT1 protein.
4. The Shredding: The tagged protein is sent to the proteasome, which acts like a biological paper shredder. The GSPT1 protein is destroyed.

By destroying GSPT1, eragidomide effectively starves the cancer cell of its ability to make new parts, leading to the death of the tumor.

FDA-Approved Clinical Indications

As eragidomide is currently in the research phase, it does not have final FDA approval for any specific disease. However, it is being studied for the following:

Oncological Uses (Investigational):

• Acute Myeloid Leukemia (AML): Specifically for patients whose cancer has come back (relapsed) or did not respond to other treatments (refractory).
• Myelodysplastic Syndromes (MDS): High-risk cases that need new treatment options.

Non-Oncological Uses:

• There are currently no non-cancer uses being studied for this drug.

Dosage and Administration Protocols

Because eragidomide is used in clinical trials, the dose is strictly managed by research doctors to find the safest and most effective amount for each patient.

Dose Adjustments:

• Renal/Hepatic Insufficiency: Since the liver and kidneys process medicines, doctors monitor these organs closely. If blood tests show the liver or kidneys are under stress, the dose may be lowered or delayed.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 have focused on patients with very difficult-to-treat leukemia.

• Response Rates: Early Phase 1 data showed that some patients with relapsed AML experienced a “Complete Remission” (no signs of cancer in the blood).
• Disease Control: In recent study updates, the drug demonstrated the ability to rapidly reduce the number of leukemia “blast” cells in the bone marrow.
• Survival: While long-term survival rates are still being collected in 2026, the drug is showing promise for patients who have exhausted all other standard chemotherapy options. Numerical data suggests that in specific genetic subgroups, the drug may work more effectively.

Safety Profile and Side Effects

Eragidomide is a powerful medicine and can cause side effects by affecting healthy blood cells.

Black Box Warning

None. (As an investigational drug, a formal Black Box Warning has not yet been assigned, but similar drugs in this class often carry warnings regarding the risk of severe birth defects).

Common Side Effects (>10%)

• Neutropenia: A drop in white blood cells, which increases the risk of infection.
• Thrombocytopenia: A drop in platelets, which can lead to easy bruising or bleeding.
• Fatigue: Feeling unusually tired or weak.
• Nausea: Feeling sick to the stomach.

Serious Adverse Events

• Febrile Neutropenia: A fever combined with low white blood cells; this is a medical emergency.
• Atrial Fibrillation: An irregular or fast heartbeat.
• Cytokine Release Syndrome (CRS): A serious immune system reaction that can cause high fever and low blood pressure.

Management: Doctors often give “growth factor” shots to help the body make more white blood cells and use blood transfusions if counts get too low.

Research Areas

In 2025 and 2026, eragidomide is being explored as part of Combination Immunotherapy. While it is not a stem cell therapy itself, researchers are looking at how this drug can “prime” the bone marrow before a Stem Cell Transplant. The goal is to clear out enough cancer cells so that a transplant has a higher chance of curing the patient.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• Bone Marrow Biopsy: To confirm the amount of cancer present.
• Complete Blood Count (CBC): To check baseline blood levels.
• EKG: To check heart rhythm before starting treatment.

Precautions During Treatment:

• Infection Control: Wash hands often and avoid crowds, as your immune system will be weakened.
• Pregnancy: Because this drug is a CELMoD, it may be very harmful to an unborn baby. Effective birth control is mandatory for both men and women.

“Do’s and Don’ts”:

• DO report any fever over 38°C (100.4°F) to your doctor immediately.
• DO keep all appointments for blood tests, as these are vital for your safety.
• DON’T start any new medications—including herbal supplements—without asking your oncology team.
• DON’T ignore any sudden changes in your heartbeat or chest pain.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice. Eragidomide is an investigational drug and is not available for general prescription. Always consult with a qualified oncologist regarding your diagnosis and treatment options. If you are experiencing a medical emergency, contact your local emergency services immediately.